ObjectiveTo evaluate the safety and efficacy of nicotinamide for the treatment of hyperphosphatemia in patients undergoing maintenance hemodialysis. MethodsAccording to the collaborative search strategy, CNKI, Wanfang Database , Weipu Database, PubMed were searched for literature about clinical trials on nicotinamide treatment for hyperphosphatemia in patients undergoing maintenance hemodialysis. After quality assessment and data extraction, Meta- analysis was conducted by RevMan 5.0. ResultsA total of 172 maintenance dialysis patients in the 5 reports were analyzed. Meta-analysis showed that the levels of serum phosphorus and calcium-phosphorus in nicotinamide group significantly lower than that in control group {［SMD=-1.02, 95%CI(-1.8, -0.23), P＜0.05］ and ［WMD =-0.86，95%CI (-1.53，-0.20)，P=0.01］}. There was no statistical difference in the levels of serum calcium and parathyroid hormone between two groups {［SMD=0.23, 95% CI(-0.08, 0.54), P=0.14］ and ［WMD=-0.54，95%CI (-1.27～-0.20)，P=0.15］} .Skin flushing, nausea, thrombocytopenia and other adverse events were found in patients treated with nicotinamide, but the symptoms disappear after drug withdrawal, the adverse events in two groups had no statistical significance. ConclusionsNicotinamide could effectively improve serum biochemical indexes in maintenance dialysis patients with hyperphosphatemia, and it is safe.

无